Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)

British Journal of Ophthalmology

Volumn 98, Issue 7, 2014, Pages 951-955

  Wykoff, Charles C ^a   Brown, David M ^a   Maldonado, Maria E ^a   Croft, Daniel E ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; CATARACT; CENTRAL SUBFIELD THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; EYE INFLAMMATION; FEMALE; GEOGRAPHIC ATROPHY; HEART ATRIUM FIBRILLATION; HUMAN; INTRARETINAL FLUID; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; SUBRETINAL FLUID; SUBRETINAL PIGMENT EPITHELIAL FLUID; TRAUMATIC CATARACT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

CLINICAL TRIAL; DEGENERATION; MACULA; NEOVASCULARISATION; RETINA;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SINGLE-BLIND METHOD; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84902362487     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304736     Document Type: Article

References (18)

1. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
4. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and Bevacizumab for treatment of Neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
5. Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology 2012;119:2537-48.
6. Brown DM, Tuomi L, Shapiro H. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina 2013;33:23-34.
7. Wykoff CC, Brown DM, Chen E, et al. SAVE (Super-dose Anti-VEGF) trial: 2.0 mg Ranibizumab for recalcitrant Neovascular age-related macular degeneration: 1-Year results. Ophthalmic Surg Lasers Imaging Retin 2013;44:121-6.
8. Wykoff CC, Brown DM, Croft DE, et al. Two year SAVE outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology 2013;120:1945-6 e1941.
9. Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013;120:349-54.
10. Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond) 2012;26:1181-7.
11. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.
12. Jaffe G. The Effect of Early, Persistent Fluid on Subsequent Visual Acuity in the VIEW 1 and VIEW 2 Studies of Neovascular AMD. American Societey of Retina Specialists Toronto, Canada, August 25th. 2013.
13. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8 e2141.
14. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014;121:188-92.
15. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013;156:15-22.
16. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovacular age-related macular degeneration. Am J Ophthalmol 2013;156:29-35.
17. Cho H, Shah CP, Weber M, et al. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013;97:1032-5.
18. Schachat AP. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. American J Ophthalmol 2013;156:1-2 e1.